211 related articles for article (PubMed ID: 33847849)
41. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
42. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
43. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
Brings A; Lehmann ML; Foerster KI; Burhenne J; Weiss J; Haefeli WE; Czock D
Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
[TBL] [Abstract][Full Text] [Related]
44. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
45. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users.
Kawano Y; Nagata M; Nakamura S; Akagi Y; Suzuki T; Tsukada E; Hoshiko M; Kujirai A; Nakamatsu S; Nishikawa T; Enomoto A; Negishi K; Shimada S; Aoyama T; Mano Y
Biol Pharm Bull; 2021; 44(5):611-619. PubMed ID: 33952817
[TBL] [Abstract][Full Text] [Related]
47. Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine.
Ngo LT; Yang SY; Shin S; Cao DT; Van Nguyen H; Jung S; Lee JY; Lee JH; Yun HY; Chae JW
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1430-1442. PubMed ID: 36193622
[TBL] [Abstract][Full Text] [Related]
48. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
Gong IY; Mansell SE; Kim RB
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
[TBL] [Abstract][Full Text] [Related]
49. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
50. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects.
Byon W; Nepal S; Schuster AE; Shenker A; Frost CE
J Clin Pharmacol; 2018 Jul; 58(7):965-971. PubMed ID: 29578609
[TBL] [Abstract][Full Text] [Related]
51. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
52. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
53. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
Hanigan S; Das J; Pogue K; Barnes GD; Dorsch MP
J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
[TBL] [Abstract][Full Text] [Related]
54. [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020].
Auditeau C; Talbot A; Blandinières A; Smadja DM; Gendron N
Bull Cancer; 2020 May; 107(5):574-585. PubMed ID: 32252973
[TBL] [Abstract][Full Text] [Related]
55. Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban.
Tsuruya Y; Nakanishi T; Komori H; Wang X; Ishiguro N; Kito T; Ikukawa K; Kishimoto W; Ito S; Schaefer O; Ebner T; Yamamura N; Kusuhara H; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2524-2534. PubMed ID: 28456731
[TBL] [Abstract][Full Text] [Related]
56. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
57. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S; Salphati L; Gomez-Zepeda D; Wanek T; Chen L; Chu X; Kunta J; Mezler M; Menet MC; Chasseigneaux S; Declèves X; Langer O; Pierre E; DiLoreto K; Hoft C; Laplanche L; Pang J; Pereira T; Andonian C; Simic D; Rode A; Yabut J; Zhang X; Scheer N
Mol Pharmacol; 2016 May; 89(5):492-504. PubMed ID: 26893303
[TBL] [Abstract][Full Text] [Related]
58. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
59. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
60. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]